US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.62

+0.09000.72%

Volume:183.63K

Turnover:2.31M

Market Cap:697.31M

PE:10.69

High:12.64

Open:12.54

Low:12.54

Close:12.53

52wk High:13.59

52wk Low:12.50

Shares:55.25M

Float Shares:55.25M

Volume Ratio:2.25

T/O Rate:0.33%

Dividend:1.42

Dividend Rate:11.22%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.87

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Heron Therapeutics Announces Second Quarter 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/RA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.62,"timestamp":1787673348439,"preClose":12.53,"halted":0,"volume":183627,"delay":0,"changeRate":0.007182761372705496,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Trading","change":0.09,"latestTime":"08-25 11:56:10 EDT","open":12.54,"high":12.64,"low":12.54,"amount":2313684.6835185,"amplitude":0.007981,"askPrice":12.62,"askSize":100,"bidPrice":12.6,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.53,"dividendRate":0.112155,"preHourTrading":{"tag":"盘前","latestPrice":12.54,"preClose":12.53,"latestTime":"08:53 EDT","volume":32,"amount":401.270112,"timestamp":1787662393874,"change":0.01,"changeRate":0.000798,"amplitude":0.000806},"postHourTrading":{"tag":"盘后","latestPrice":12.53,"preClose":12.53,"latestTime":"19:30 EDT","volume":16,"amount":200.5204,"timestamp":1787614206669,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.246462},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.246462,"shares":55254696,"dividePrice":1.4154,"high":12.64,"amplitude":0.007981,"preClose":12.53,"low":12.54,"week52Low":12.5,"pbRate":"0.87","week52High":13.59,"institutionHeld":0,"latestPrice":12.62,"eps":1.18,"divideRate":0.112155,"volume":183627,"delay":0,"ttmEps":1.18,"open":12.54,"prevYearClose":12.96,"prevWeekClose":12.55,"prevMonthClose":12.81,"prevQuarterClose":12.88,"fiveDayClose":12.63,"twentyDayClose":12.79,"sixtyDayClose":12.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-09-10","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-10","defaultRemindTime":1789047000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1789012800000,"payDate":"2026-09-24"},{"date":"2026-08-06","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-20","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-20"},{"date":"2026-07-09","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-09","defaultRemindTime":1783603800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-09","currency":"USD","dateTimestamp":1783569600000,"payDate":"2026-07-23"},{"date":"2026-06-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"date":"2026-05-07","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-07","defaultRemindTime":1778160600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-21","payableDate":"2026-05-07","currency":"USD","dateTimestamp":1778126400000,"payDate":"2026-05-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660178421","title":"Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660178421","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660178421?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:26","pubTimestamp":1787142360,"startTime":"0","endTime":"0","summary":"Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected byyear-end RA is a $24 billion m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347616/0/en/chemomab-therapeutics-announces-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTRS","LENZ","BK4539","RA","BK4139","BK4007","PSC","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659009089","title":"Press Release: First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659009089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659009089?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:15","pubTimestamp":1786565700,"startTime":"0","endTime":"0","summary":"-- Completed enrollment for Cohort 1  of Phase 1b ANB033. trial in celiac disease ; top-line Cohort 1 data reaffirmed for Q4. -- Cohort 2  enhanced to enroll up to 40 patients including. those with a broad range of histologic  and symptom. severity to further inform future development; top-line Cohort 2 data. -- U.S. FDA granted Fast Track designation for ANB033 for the treatment of. -- Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis. -- Reiterating cash-runway into Q2 2028, including the expansion of ANB033. -- U.S. FDA granted Fast Track designation to ANB033 for the. treatment of people with CeD on a gluten-free diet. -- 70-patient trial assessing one dose level of subcutaneously. -- Cohort 1  is a gluten-challenge study to assess the. -- Cohort 2  assesses the possibility of mucosal healing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLE","BK4077","TRAX","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658915593","title":"Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658915593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658915593?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:30","pubTimestamp":1786455000,"startTime":"0","endTime":"0","summary":"placebo-controlled Phase 3 registrational trial with an open-label. extension assessing the efficacy and safety of telitacicept in gMG. -- Topline data anticipated in 1H 2027Primary Sjgren's Disease-- UPSTREAM SjD. efficacy and safety of telitacicept in SjDCorporate Updates-- Appointed David Zaccardelli, Pharm.D., former Chief Executive Officer and. President of Verona Pharma, to its Board of Directors. approved telitacicept for the treatment of adult patients with SjD and. -- Results from the Phase 3 TELIGAN trial evaluating telitacicept in IgAN in. China were published in The New England Journal of MedicineSecond Quarter 2026 Financial Results-- Cash Position: Cash, cash equivalents and marketable securities were. $466.1 million as of June 30, 2026, which together with the $48.4 million. net proceeds from at-the-market sales during July 2026, are projected to. -- Research & Development (R&D) Expenses: R&D expenses for the second. quarter of 2026 were $25.9 million, compared to $261.5","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","VOR","BK4139","BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658693652","title":"Heron Therapeutics Announces Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658693652","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658693652?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF net revenue grew 35% and APONVIE net revenue grew 74% year-over-year – Amended credit facility with Hercules Capi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341780/0/en/heron-therapeutics-announces-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","CINV","HRTX","BK4563","BK4139","BK4161","IE0031619046.USD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","MEC","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":14,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RA\",params:#limit:6,delay:false,,,undefined,":[]}}